|
Clinical trial evaluating brain cancer vaccine is underway at NYU
October 22, 2007A clinical trial evaluating a brain cancer vaccine in patients with newly diagnosed brain cancer has begun at NYU Medical Center. The study will evaluate the addition of the vaccine following standard therapy with surgery and chemotherapy in patients with glioblastoma multiforme, a deadly form of brain cancer.
The vaccine, called DCVax-Brain, incorporates proteins found in patients' tumors and is designed to attack cancer cells containing these proteins. The study underway at NYU Medical Center is an expansion of an earlier phase I trial of the vaccine. The vaccine is made by the Northwest Biotherapeutics, Inc., based in Bothell, Washington.
"We are really excited about the promise of this vaccine," said Patrick J. Kelly, M.D., the chairman of the Department of Neurosurgery and the Joseph Ransohoff Professor of Neurosurgery at NYU School of Medicine. "Everything now depends on something in addition to surgery so that these tumors do not recur. A cancer vaccine like this may make a difference in extending life and maintaining a good quality of life."
"This is a form of individualized therapy," adds NYU neuro-oncologist Michael Gruber, M.D. "There is a lot of promise with this approach," he says. He and Dr. Kelly will be the lead investigators conducting the trial at NYU.
Despite surgery and chemotherapy, patients with glioblastoma multiforme brain cancer typically survive about 15 months. Even if only a small number of tumor cells are left in the brain, that is enough for these fast growing and aggressive tumors to grow back. The tumors do not grow elsewhere in the body. "It is so frustrating," notes Dr. Kelly, "because brain tumors don't metastasize like other tumors. They recur locally but we just can't cure it."
A brain cancer vaccine is intended as a kind of immunotherapy, which means that it primes the patient's own immune system to kill proteins found in cancer cells. The trial will enroll patients 18 to 65 years old with newly diagnosed glioblastoma multiforme brain cancer who will receive standard primary treatment with surgery followed by radiation with concurrent chemotherapy. Enrolled patients will be randomized to receive the standard of care, and others will receive the standard of care and the vaccine.
The vaccine will be made from the tumors and immune cells of each patient. When a patient's tumor is removed during surgery it will be shipped to a laboratory where the tumor cells will be broken up to prepare the first component of the vaccine. Separately, patients' dendritic cells, a powerful type of immune cell, will be obtained and sent to a laboratory for purification. Dendritic cells may be able to teach the immune system to recognize and destroy cancer cells. The patients' tumor cell material is combined with the dendritic cells to form the vaccine.
New York University Medical Center and School of Medicine
"This is a form of individualized therapy," adds NYU neuro-oncologist Michael Gruber, M.D. "There is a lot of promise with this approach," he says. He and Dr. Kelly will be the lead investigators conducting the trial at NYU.
Despite surgery and chemotherapy, patients with glioblastoma multiforme brain cancer typically survive about 15 months. Even if only a small number of tumor cells are left in the brain, that is enough for these fast growing and aggressive tumors to grow back. The tumors do not grow elsewhere in the body. "It is so frustrating," notes Dr. Kelly, "because brain tumors don't metastasize like other tumors. They recur locally but we just can't cure it."
A brain cancer vaccine is intended as a kind of immunotherapy, which means that it primes the patient's own immune system to kill proteins found in cancer cells. The trial will enroll patients 18 to 65 years old with newly diagnosed glioblastoma multiforme brain cancer who will receive standard primary treatment with surgery followed by radiation with concurrent chemotherapy. Enrolled patients will be randomized to receive the standard of care, and others will receive the standard of care and the vaccine.
The vaccine will be made from the tumors and immune cells of each patient. When a patient's tumor is removed during surgery it will be shipped to a laboratory where the tumor cells will be broken up to prepare the first component of the vaccine. Separately, patients' dendritic cells, a powerful type of immune cell, will be obtained and sent to a laboratory for purification. Dendritic cells may be able to teach the immune system to recognize and destroy cancer cells. The patients' tumor cell material is combined with the dendritic cells to form the vaccine.
New York University Medical Center and School of Medicine
Brain Cancer News and Current Brain Cancer Events RSSCancer-killing viruses influence tumor blood-vessel growth
Viruses genetically designed to kill cancer cells offer a promising strategy for treating incurable brain tumors such as glioblastoma, but the body's natural defenses often eliminate the viruses before they can eliminate the tumor.
Researchers uncover mechanism of action of antibiotic able to reduce neuronal cell death in brain
Virginia Commonwealth University researchers have discovered how an antibiotic works to modulate the activity of a neurotransmitter that regulates brain functions, which eventually could lead to therapies to treat Alzheimer's disease, Huntington's disease, epilepsy, stroke, dementia and malignant gliomas.
Researchers discover gene for branchio-oculo-facial syndrome
In a collaborative effort, researchers from Boston University School of Medicine (BUSM) have discovered that deletions or mutations within the TFAP2A gene (Activating Enhancer-Binding Protein) result in the distinctive clefting disorder Branchio-Oculo-Facial syndrome (BOFS).
Cancer cells spread by releasing 'bubbles', according to an MUHC study
A new fundamental mechanism of how tumour cells communicate has just been discovered by the team of Dr. Janusz Rak at the Research Institute of the McGill University Health Centre (MUHC) in collaboration with Dr Guha from the University of Toronto.
NovoCure presents results from breast cancer pilot study
NovoCure announced today that it presented the results from a single-arm pilot trial evaluating the Novo-TTF, a non-invasive portable medical device, combined with neo-adjuvant chemotherapy for the treatment of patients with locally advanced breast cancer.
Brain study may lead to improved epilepsy treatments
Using a rodent model of epilepsy, researchers found one of the body's own neurotransmitters released during seizures, glutamate, turns on a signaling pathway in the brain that increases production of a protein that could reduce medication entry into the brain.
Protein protects embryonic stem cells' versatility and self-renewal
A protein known as REST blocks the expression of a microRNA that prevents embryonic stem cells from reproducing themselves and causes them to differentiate into specific cell types, scientists at The University of Texas M. D. Anderson Cancer Center report in the journal Nature.
Tumor-killing virus selectively targets diseased brain cells
New findings show that a specialized virus with the ability to reproduce its tumor-killing genes can selectively target tumors in the brains of mice and eliminate them.
Report identifies research to bolster knowledge of health effects of wireless communication devices
The rapid increase in the use of wireless communication devices in recent years has been accompanied by a significant amount of research into potential health effects from high exposure to radiofrequency (RF) energy emitted by these devices.
Study identifies novel gene alterations in lung cancer
An international team of scientists, supported in part by the National Human Genome Research Institute (NHGRI), one of the National Institutes of Health (NIH), today announced that its systematic effort to map the genomic changes underlying lung cancer has uncovered a critical gene alteration not previously linked to any form of cancer.
More Brain Cancer News Articles
 | Death Be Not Proud (P.S.) by John Gunther |
 | Halfway to Forever (Forever Faithful Series #3) by Karen Kingsbury |
 | Chasing Daylight by Gene O'Kelly |
 | Blindsided: Lifting a Life Above Illness: A Reluctant Memoir by Richard M. Cohen |
 | The Cholesterol Hoax by Sherry Rogers |
 | Surviving Terminal Cancer: Clinical Trials, Drug Cocktails, and Other Treatments Your Oncologist Won't Tell You About by Ben A. Williams |
 | Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by H. Charles Wolf |
 | Brain Tumors: Leaving the Garden of Eden--A Survival Guide to Diagnosis, Learning the Basics, Getting Organized, and Finding Your Medical Team by Paul M. Zeltzer |
 | Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black |
 | Plant A Geranium In Your Cranium by Barbara Johnson |
| © 2008 BrightSurf.com |